Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00054561 · ClinicalTrials.gov registry record · Phase 3

Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer

A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.

Completed
Registry status
Phase 3
Development phase

NCT00054561 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00054561, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.

COMPLETED
Registry status
Phase 3
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy such as isotretinoin use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of tumor cells. Vitamin E may be able to decrease side effects caused by isotretinoin. It is not yet known whether combining isotretinoin and interferon alfa with vitamin E is more effective than observation in preventing recurrence of head and neck cancer after surgery and/or radiation therapy. PURPOSE: Randomized phase III trial to compare the effectiveness of isotretinoin and interferon alfa combined with vitamin E with that of observation in treating patients who have undergone surgery and/or radiation therapy for stage III or stage IV head and neck cancer.

Interventions

  • PROCEDURE adjuvant therapy
  • BIOLOGICAL recombinant interferon alfa
  • DIETARY_SUPPLEMENT vitamin E
  • DRUG isotretinoin

Trial Details

FieldValue
Start Date 2003-11-26
Est. Completion 2009-05-01
Phase Phase 3

Sponsor

Eastern Cooperative Oncology Group

141 total trials

What the Registry Record Tells You About NCT00054561

The ClinicalTrials.gov registry entry for NCT00054561 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which adjuvant therapy is the first listed.

NCT00054561 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00054561 about?

NCT00054561 is a clinical study titled "Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer". RATIONALE: Drugs used in chemotherapy such as isotretinoin use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of tumor cells. Vitamin E may be able to decrease side effects caused by isotretinoin. It is not yet known whethe...

What is the current status of trial NCT00054561?

This trial is currently completed. It is a Phase 3 study. The study started on 2003-11-26. Estimated completion is 2009-05-01.

What interventions are being tested in trial NCT00054561?

The interventions under investigation include: adjuvant therapy (PROCEDURE), recombinant interferon alfa (BIOLOGICAL), vitamin E (DIETARY_SUPPLEMENT), isotretinoin (DRUG).

Who is sponsoring clinical trial NCT00054561?

This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.